comparemela.com

Latest Breaking News On - Kidney cancer program - Page 2 : comparemela.com

DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell RCC

The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.

United statesSumanta kumar palBladder cancer disease teamKidney cancer programDatabase consortiumInternational metastaticMedical oncologyTherapeutics researchHope comprehensive cancer center

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Sumanta kumar palKidney cancer programTherapeutics researchDepartment of medical oncologyBladder cancer disease teamMedical oncology

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.

United statesSan franciscoToni choueiriDorothy byrnePaulv viscuseRobert motzerNancy kohlbergHarvard medical schoolGenitourinary tumors multidisciplinary clinic centerMemorial sloan kettering cancer centerInternational metastatic renal cell carcinoma database consortiumLank centerCancer research of the national instituteGenitourinary oncology serviceGenitourinary oncology at dana farber cancer instituteUniversity of virginia

Drug targeting clear cell renal cell carcinoma shows promising approach

In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively di

United statesRobert lewis kirbyNizarm tannirJames brugarolasDivision of hematologySherry wigley crow cancer researchSimmons cancer centerSouthwestern medical centerKidney cancer programArrowhead pharmaceuticalsClinical cancer researchNational cancer instituteKidney cancer specialized program of research excellenceHaroldc simmons comprehensive cancer centerBrugarolas labUniversity of texas md anderson cancer center

Race Associated With Kidney Cancer Survival Disparities

Across disease stages, Black patients with renal cell carcinoma experience worse survival outcomes than White patients, research has shown.

United statesAmerican society of clinical oncology meetingNational cancer databaseKidney cancer program at johns hopkins medicineUrologic oncologyOriginal investigationsPossible treatment identifiedRare kidney cancerNirmish singlaKidney cancer programJohns hopkins medicineClinical oncology meetingClinical oncologyUrologist when discussing kidneyKidney cancerKidney cancer disparities

vimarsana © 2020. All Rights Reserved.